The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis

被引：0
|
作者：
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S245 / S245
页数：1
相关论文
共 50 条
  • [1] The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY)
    Giovannoni, G.
    Cook, S.
    Rieckmann, P.
    Vermersch, P.
    Soelberg-Sorensen, P.
    Comi, G.
    Chang, P.
    Lopez-Bresnahan, M.
    Kim, R.
    JOURNAL OF NEUROLOGY, 2006, 253 : 99 - 99
  • [2] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [3] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
    Giovannoni, G.
    Cook, S.
    Greenberg, S.
    Chang, P.
    Comi, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206
  • [4] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
    Rieckmann, Peter
    Giovannoi, Gavin
    Cook, Stuart D.
    Greenberg, S.
    Chang, Peter
    Comi, Giancarlo
    Sorensen, Per Soelberg
    Vermersch, Patrick
    MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
  • [5] Cladribine tablets treating multiple sclerosis orally (CLARITY): an independent analysis of the quality of life data
    Afolabi, D.
    Albor, C.
    Altmann, D. R.
    Zalewski, L.
    Baker, D.
    Schmierer, K.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 423 - 423
  • [6] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Comi, Giancarlo
    Cook, Stuart D.
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony C.
    Viglietta, Vissia
    Greenberg, Steven J.
    JOURNAL OF NEUROLOGY, 2013, 260 (04) : 1136 - 1146
  • [7] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Giancarlo Comi
    Stuart D. Cook
    Gavin Giovannoni
    Kottil Rammohan
    Peter Rieckmann
    Per Soelberg Sørensen
    Patrick Vermersch
    Anthony C. Hamlett
    Vissia Viglietta
    Steven J. Greenberg
    Journal of Neurology, 2013, 260 : 1136 - 1146
  • [8] Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis
    Li, Haifeng
    Zhang, Xu
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (18): : 1738 - 1739
  • [9] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [10] Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
    Rammohan, Kottil
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony
    Kurukulasuriya, Nuwan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2012, 1 (01) : 49 - 54
12345